It refers to a type of breast cancer that does not respond to hormone therapy. This cancer lacks progesterone or estrogen receptors. It also lacks the protein HER2. Because it lacks either of these hormone receptors, it is resistant to hormonal treatments. If you have Triple Negative Breast Cancer, there are treatments available.
The risk of triple-negative breast cancer is increased by inherited mutations in the BRCA1 and BRCA2 genes. Carriers of these mutations have an increased risk of developing breast, ovarian, and prostate cancer. However, triple-negative breast cancer does not occur in all cases of BRCA mutations. It is important to note that genetic tests cannot predict triple-negative breast cancer. The onset of this cancer may be hereditary or acquired, so it is important to seek a genetic testing provider if you suspect you may be affected by this mutation.
The BRCA1 mutation causes triple-negative breast cancer in women who are younger than 40 years old. While a family history of this cancer is not necessarily predictive of the likelihood of developing this disease, African-American women are more likely to develop the condition than any other ethnic group. It is a very interesting cancer type that has been the focus of intense research. The disease is not uncommon in African-American women and is a major source of fascination for researchers.
In addition to the mutation of the HER-2 protein, the her-2 neu gene also affects the growth of triple-negative breast cancer. In mice with the EGLN2 gene depleted, tumors grow slower. These findings suggest that the EGLN2 protein may have a role in triple-negative breast cancer. The tumors of triple-negative patients are highly expressed in the EGLN2 gene. The genetic mutation could lead to a more effective treatment.
Dr. Carey is an expert on triple-negative breast cancer. His experience includes chemotherapy and intensive anthracycline/taxane regimens. The benefits of chemotherapy for triple-negative breast cancer depend on the stage of the tumor. However, Dr. Carey advises patients to keep the results of their breast cancer and to analyze them again. It’s essential to look at subsets when analyzing breast cancer.
Adding veliparib to carboplatin has not been proven to improve the pathologic complete response rate, event-free survival, or overall survival. This study compared carboplatin alone with carboplatin and veliparib in 634 patients with stage II or III operable triple-negative breast cancer. Although no statistically significant difference was observed between carboplatin alone and carboplatin plus veliparib, the results of this trial are encouraging.
